Product Characteristics and Pharmacological Profile of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma in the Phase II Registrational ZUMA-2 Trial

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2020年 / 18卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：4 / 6
页数：3
相关论文
共 50 条
  • [31] KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results
    Shah, Bijal D.
    Bishop, Michael R.
    Oluwole, Olalekan O.
    Logan, Aaron C.
    Baer, Maria R.
    Donnellan, William B.
    O'Dwyer, Kristen M.
    Holmes, Houston
    Arellano, Martha L.
    Ghobadi, Armin
    Pagel, John M.
    Lin, Yi
    Cassaday, Ryan D.
    Park, Jae H.
    Abedi, Mehrdad
    Castro, Januario E.
    DeAngelo, Daniel J.
    Malone, Adriana K.
    Mawad, Raya
    Schiller, Gary J.
    Rossi, John M.
    Bot, Adrian
    Shen, Tong
    Goyal, Lovely
    Jain, Rajul K.
    Vezan, Remus
    Wierda, William G.
    BLOOD, 2021, 138 (01) : 11 - 22
  • [32] Cost-Effectiveness of KTE-X19 Car T Therapy Following Bruton Tyrosine Kinase Inhibitor Treatment for Relapsed/Refractory Mantle Cell Lymphoma in England
    Maglinte, Gregory A.
    Simons, Claire L.
    Wang, Michael
    Wade, Sally W.
    Brown, Martin
    Petersohn, Svenja
    Bennison, Craig
    Dreyling, Martin
    BONE MARROW TRANSPLANTATION, 2021, 56 (SUPPL 1) : 195 - 196
  • [33] Updated Phase 1 Results of Zuma-3: Kte-X19, an Anti-CD19 Chimeric Antigen Receptor T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
    GWierda, William
    Bishop, Michael R.
    Oluwole, Olalekan
    Logan, Aaron C.
    Baer, Maria R.
    Donnellan, William B.
    O'Dwyer, Kristen M.
    Castro, Januario E.
    Schiller, Gary J.
    Holmes, Houston
    Abedi, Mehrdad
    Ghobadi, Armin
    Arellano, Martha L.
    Malone, Adriana K.
    Pagel, John M.
    Mardiros, Armen
    Shen, Tong
    Vezan, Remus
    Jain, Rajul K.
    Shah, Bijal D.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
  • [34] Phase 2 Trial of Rituximab and Bortezomib in Patients With Relapsed or Refractory Mantle Cell and Follicular Lymphoma
    Baiocchi, Robert A.
    Alinari, Lapo
    Lustberg, Mark E.
    Lin, Thomas S.
    Porcu, Pierluigi
    Li, Xiaobai
    Johnston, Jeffrey S.
    Byrd, John C.
    Blum, Kristie A.
    CANCER, 2011, 117 (11) : 2442 - 2451
  • [35] Phase 2 trial of umbralisib, ublituximab, and venetoclax in patients with relapsed/refractory mantle cell lymphoma
    Wallace, Danielle S.
    Rowland, Chris
    Hill, Brian T.
    Baran, Andrea M.
    Casulo, Carla
    Reagan, Patrick M.
    Winter, Allison
    Karmali, Reem
    Winter, Jane N.
    Gordon, Leo I.
    Bui, Andrew
    Sportelli, Peter
    Miskin, Hari P.
    Weiss, Michael S.
    Friedberg, Jonathan W.
    Ma, Shuo
    Barr, Paul M.
    LEUKEMIA & LYMPHOMA, 2023,
  • [36] ZUMA-8: A Phase 1 Study of KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
    Davids, Matthew S.
    Kenderian, Saad S.
    Flinn, Ian W.
    Hill, Brian T.
    Maris, Michael
    Ghia, Paolo
    Byrne, Michael
    Bartlett, Nancy L.
    Pagel, John M.
    Zheng, Yan
    Kanska, Justyna
    Zhang, Wangshu
    Masouleh, Behzad Kharabi
    Granados, Enrique
    Ibarz, Javier Pinilla
    BLOOD, 2022, 140 : 7454 - 7456
  • [37] Outcomes of Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Treated with Brexucabtagene Autoleucel (Brexu-cel) in ZUMA-2 and ZUMA-18, an Expanded Access Study
    Goy, Andre
    Jacobson, Caron A.
    Flinn, Ian W.
    Hill, Brian T.
    Weng, Wen-Kai
    Mountjoy, Luke
    Olalekan, Oluwole
    Zheng, Dan
    Nunes, Ana
    Zhang, Wangshu
    Shen, Rhine R.
    Kloos, Ioana
    Wang, Michael L.
    BLOOD, 2023, 142
  • [38] KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
    Shah, Bijal D.
    Ghobadi, Armin
    Oluwole, Olalekan O.
    Logan, Aaron C.
    Boissel, Nicolas
    Cassaday, Ryan D.
    Leguay, Thibaut
    Bishop, Michael R.
    Topp, Max S.
    Tzachanis, Dimitrios
    O'Dwyer, Kristen M.
    Arellano, Martha L.
    Lin, Yi
    Baer, Maria R.
    Schiller, Gary J.
    Park, Jae H.
    Subklewe, Marion
    Abedi, Mehrdad
    Minnema, Monique C.
    Wierda, William G.
    DeAngelo, Daniel J.
    Stiff, Patrick
    Jeyakumar, Deepa
    Feng, Chaoling
    Dong, Jinghui
    Shen, Tong
    Milletti, Francesca
    Rossi, John M.
    Vezan, Remus
    Masouleh, Behzad Kharabi
    Houot, Roch
    LANCET, 2021, 398 (10299): : 491 - 502
  • [39] Cost-effectiveness analysis of KTE-X19 CAR T therapy versus real-world standard of care in patients with relapsed/refractory mantle cell lymphoma post BTKi in England
    Petersohn, Svenja
    Salles, Gilles
    Wang, Michael
    Wu, Jim
    Wade, Sally W.
    Simons, Claire L.
    Bennison, Craig
    Siddiqi, Rubina
    Peng, Weimin
    Kloos, Ioana
    Castaigne, Gab
    Hess, Georg
    JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) : 730 - 740
  • [40] Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma
    Fisher, Richard I.
    Bernstein, Steven H.
    Kahl, Brad S.
    Djulbegovic, Benjamin
    Robertson, Michael J.
    de Vos, Sven
    Epner, Elliot
    Krishnan, Amrita
    Leonard, John P.
    Lonial, Sagar
    Stadtmauer, Edward A.
    O'Connor, Owen A.
    Shi, Hongliang
    Boral, Anthony L.
    Goy, Andre
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (30) : 4867 - 4874
12345